SeamlessBio · Albumin Portfolio · Complete Grade Comparison
HSA vs rHSA — Human Serum Albumin vs Recombinant HSA: Which Grade for Your Application?
SeamlessBio supplies both native Human Serum Albumin (HSA) and three grades of recombinant Human Serum Albumin (rHSA) — each with different expression systems, purity profiles, regulatory documentation, and optimal application areas. This guide explains the differences mechanistically and maps each grade to the right application.
Buy albumin – HSA, rHSA and BSA from EU stock
Request a quote or a free test sample – EU stock, lot reservation up to 36 months.
Plasma-derived
Human Serum Albumin (HSA)
Native plasma fraction — View product →
Purified from pooled human plasma by Cohn fractionation or ion exchange chromatography. Contains native HSA with full post-translational modifications and glycation profile matching physiological human albumin.
- IVD calibrators and controls — matched human matrix
- Immunoassay blocking — species-matched
- Pharmaceutical drug binding studies
- Clinical laboratory reference material
- Requires donor screening documentation per IVDR
Recombinant · Rice-expressed
rHSA Premium Grade
Oryza sativa (rice) expression — View product →
Highest purity rHSA. Expressed in Oryza sativa (rice) seed — the most established recombinant HSA production system with FDA and EMA precedent. No animal-derived components. ISO 13485 documentation.
- GMP cell therapy manufacturing — xeno-free supplement
- iPSC cryopreservation medium
- Clinical-grade ATMPs — EMA Annex I xeno-free path
- AAV formulation buffer — prevents capsid adsorption
- Pharmaceutical formulation — drug stability excipient
Recombinant · Yeast-expressed
rHSA Economy Grade
Saccharomyces cerevisiae — View product →
Cost-effective research-grade rHSA produced in S. cerevisiae. No animal-derived components. Suitable for research applications and process development where GMP-grade documentation is not required.
- Serum-free research cell culture supplement
- Process development for xeno-free protocols
- Neural differentiation media (N2/B27 supplement)
- ELISA protein stabilisation in research context
- Protein carrier in research-grade formulation buffers
Recombinant · CHO-expressed
rHSA CHO-Expressed
Chinese hamster ovary cells — View product →
Mammalian expression system providing a glycosylation profile closer to native human albumin than yeast or plant systems. Suited to applications where glycosylation state influences function or where CHO-expressed reference material is specified.
- Drug binding studies where glycosylation affects binding
- Biosensor reference material
- Pharmacokinetic modelling requiring mammalian-expressed HSA
- Assay development where glycan profile is specified
Complete Feature Comparison — All HSA and rHSA Grades
| Feature | Native HSA | rHSA Premium (Rice) | rHSA Economy (Yeast) | rHSA CHO |
|---|---|---|---|---|
| Source | Human plasma — pooled donors | Oryza sativa (rice) seed | S. cerevisiae (baker's yeast) | CHO cells (mammalian) |
| Xeno-free | ✗ Human-derived | ✓ No animal origin | ✓ No animal origin | ⚠ CHO is mammalian |
| Animal-origin-free | ✗ | ✓ Plant expression | ✓ Microbial expression | ✗ Mammalian cells |
| Purity | ≥97% | ≥99% — highest | ≥96% | ≥97% |
| Endotoxin | ≤5 EU/mg | ≤1 EU/mg — lowest | ≤5 EU/mg | ≤5 EU/mg |
| Glycosylation | Native human glycosylation | None (plant-expressed) | None (yeast-expressed) | Mammalian glycosylation |
| ISO 13485 documentation | On request | ✓ Available | ✗ | On request |
| GMP suitability | Yes — with donor documentation | ✓ Preferred xeno-free GMP | Research only | Case by case |
| Donor screening required | ✓ HIV, HBV, HCV per lot | ✗ Not applicable | ✗ Not applicable | ✗ Not applicable |
| Blood-borne pathogen risk | Theoretical — per donor pool | None | None | None |
| Lot-to-lot consistency | Moderate — donor pool dependent | High — recombinant production | High — recombinant production | High — recombinant production |
| Relative cost | Moderate | Higher — GMP documentation included | Lowest — research grade | Moderate-high |
| IVDR IVD calibrator | ✓ Native human matrix | ⚠ Different glycosylation | ⚠ Different glycosylation | ⚠ Check assay performance |
| EMA xeno-free ATMP path | ✗ Human-derived | ✓ Preferred | ✗ Research only | ⚠ Case by case |
Application Mapping — Which Grade for Which Use Case
| Application | Recommended Grade | Reason |
|---|---|---|
| GMP CAR-T / ATMP manufacturing — xeno-free albumin supplement | rHSA Premium Grade | No animal-derived components. ISO 13485 documentation. EMA Annex I xeno-free compliance. Lowest endotoxin ≤1 EU/mg. |
| GMP iPSC cryopreservation medium | rHSA Premium Grade | Defined xeno-free cryoprotectant. No donor variability. GMP documentation package available. |
| AAV / viral vector formulation buffer | rHSA Premium Grade | Prevents AAV capsid adsorption to surfaces at 0.001–0.01%. No blood-borne pathogen contamination risk in viral vector product. |
| Pharmaceutical drug formulation — albumin excipient | rHSA Premium Grade or Native HSA | rHSA Premium for xeno-free defined formulations. Native HSA where human plasma-derived reference is specified in regulatory dossier. |
| IVD calibrators and assay controls | Native HSA | Species-matched human matrix with native glycosylation. Required for matrix-matched calibrators in IVDR submissions. |
| Immunoassay blocking — human matrix | Native HSA | Human serum albumin provides species-matched blocking for assays using anti-human antibodies or human-specific secondary detection. |
| Drug-protein binding studies (pharmacokinetics) | rHSA CHO-Expressed or Native HSA | CHO for mammalian glycosylation profile. Native HSA when plasma-derived reference is required for PK modelling. |
| Serum-free research cell culture supplement | rHSA Economy Grade | Cost-effective albumin carrier for serum-free media — no animal components, defined, lot-consistent. Research documentation sufficient. |
| Neural differentiation media (N2/B27) | rHSA Economy Grade | Serum-free protein stabiliser in N2/B27-supplemented neural differentiation medium. No endogenous growth factors from serum. |
| Process development for xeno-free GMP protocols | rHSA Economy Grade → scale to Premium Grade | Economy for initial protocol development. Switch to Premium Grade for GMP implementation — same rHSA format, higher documentation standard. |
HSA vs rHSA — Key Mechanistic Differences
The choice between native HSA and recombinant rHSA is not simply a regulatory preference — there are functional differences that matter for specific applications.
| Parameter | Native HSA (plasma-derived) | rHSA (recombinant) |
|---|---|---|
| Glycosylation | Native human glycosylation — Asn-linked glycans present. Glycosylation affects binding affinity for some drugs and ligands. | Plant- and yeast-expressed rHSA: not glycosylated. CHO-expressed rHSA: mammalian glycosylation profile. Functional differences for glycan-dependent interactions. |
| Fatty acid content | Variable — plasma fatty acid composition reflects donor diet. Can be defatted for specific applications (BSA Fatty Acid-Free equivalent). | Generally lower endogenous fatty acid content than plasma-derived HSA — more consistent lipid-binding capacity lot-to-lot. |
| Drug binding | Full native drug binding sites I and II — Sudlow sites. Glycosylation and native folding affect some drug affinities. | rHSA binding is functionally equivalent for most pharmaceutical applications. Minor differences in affinity for specific ligands reported in some studies. |
| Donor pool variability | Lot variation reflects donor pool. Age, gender, disease status of donors affects albumin glycation state and minor protein modifications. | Recombinant production eliminates donor variability — defined primary sequence, controlled production environment, consistent lot-to-lot profile. |
| Regulatory path (ATMP) | Blood-derived material under EU Blood Directive. Donor documentation required for EMA ATMP submissions. Not preferred for xeno-free path. | rHSA Premium Grade (rice): EMA-precedented xeno-free path for ATMPs. Eliminates donor documentation complexity. Preferred under EMA Annex I xeno-free framework. |
Frequently Asked Questions
What is the difference between rHSA Premium Grade and rHSA Economy Grade?
rHSA Premium Grade is expressed in Oryza sativa (rice) — the most regulatory-established plant expression system for recombinant HSA, with FDA and EMA precedent in pharmaceutical formulations. It has the highest purity (≥99%), lowest endotoxin (≤1 EU/mg), and comes with full ISO 13485 documentation for GMP applications including cell therapy manufacturing, ATMP formulation, and clinical cryopreservation. rHSA Economy Grade is expressed in Saccharomyces cerevisiae — suitable for research applications and process development where GMP documentation is not required. Cost is significantly lower. For GMP implementation, always use Premium Grade.
When should I use native HSA instead of rHSA?
Native HSA is preferred when: (1) a human plasma-derived albumin matrix is specifically required — e.g. IVD calibrators and controls where matrix matching to native human serum is critical for assay performance; (2) the application requires native HSA glycosylation — most drug binding studies and pharmacokinetic modelling use plasma-derived HSA; (3) existing regulatory dossiers reference plasma-derived HSA specifically. For all new xeno-free and GMP cell therapy applications, rHSA Premium Grade is the preferred choice.
Is rHSA CHO-expressed truly xeno-free?
No — rHSA CHO-Expressed is produced in Chinese Hamster Ovary cells, which are animal-derived. CHO-expressed rHSA therefore contains potential animal-origin contaminants and does not qualify as xeno-free under EMA Annex I definitions. For xeno-free GMP applications, use rHSA Premium Grade (rice-expressed) or rHSA Economy Grade (yeast-expressed). CHO-expressed rHSA is chosen when the mammalian glycosylation profile is functionally important for the application.
Why is rHSA used in AAV formulation buffers?
AAV capsids adsorb strongly to plastic and glass surfaces during downstream processing, filtration, and storage — causing yield losses. Albumin at 0.001–0.01% in formulation buffers forms a protein monolayer on container surfaces that competitively blocks capsid adsorption. rHSA Premium Grade is specified for AAV formulation because it has no blood-borne pathogen contamination risk (critical for a gene therapy vector product), lowest endotoxin of any albumin grade, and ISO 13485 GMP documentation for the formulation regulatory file.
Can rHSA replace BSA in cell culture applications?
For xeno-free and human-matrix applications, yes — rHSA is the appropriate albumin supplement in serum-free human cell culture, iPSC maintenance, neural differentiation, and T cell expansion media. For applications where BSA (bovine serum albumin) is specified — e.g. ELISA blocking, PBMC flow cytometry buffer, fatty acid studies requiring BSA Fatty Acid-Free — BSA remains the standard because of its specific binding properties and long-established protocol context. rHSA does not have identical fatty acid binding characteristics to BSA Fatty Acid-Free, which is relevant for lipid biology applications.
Request HSA / rHSA Samples for Your Application
All four grades available as free test samples. ISO 13485 documentation and CoA per lot. Free consultation on grade selection for your specific application.
Email: info@seamlessbio.de | +49 851 37932226
English
Deutsch